Terrestrial Bio, Inc.
PrivateLast Round
Series C
Mar 25, 2026
Total Funding Raised
$138.93M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Terrestrial Bio, Inc. is a biotechnology company that develops a proprietary microarray patch platform for the needle-free and refrigeration-free delivery of therapeutics, including GLP-1 receptor agonists and vaccines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Advanced Materials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Terrestrial Bio, Inc. Comparables
Compare Terrestrial Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Micron Biomedical | 89% | |
| Verndari, Inc. | 84% | |
| WCC Biomedical | 83% |
Terrestrial Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 25, 2026 | ||||
| Early Funding | Apr 9, 2025 | ||||
| VC Round | May 22, 2024 | ||||
| Early Funding | Sep 13, 2023 | ||||
| Series B Extension | Jan 10, 2023 | ||||
Series B | Nov 2, 2022 |
Terrestrial Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B |
| RA Capital Management | Early Funding, VC Round, Series B Extension, Series B, Series C |
| The Engine | Series B, Early Funding, Series B Extension, Series A |
| Engine Ventures | Series B, Early Funding, Series C, VC Round, Series A |
| NIH RADx | Grant |
| BioInnovation Capital | Series A, Series B Extension |
| Massachusetts Life Sciences Center | Debt, Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Grew 31% QoQ, from 90 to 118 employees.
- Jul 30, 2026
Grew 30% quarter-over-quarter, from 86 to 112 employees.
Terrestrial Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Terrestrial Bio, Inc.'s valuation, stock price, and market status.
Is Vaxess a public or private company?
Vaxess is a private company.
What is the current stock price of Vaxess?
Vaxess is a private company with no public stock price. No recent secondary market data is available.
How much is Vaxess worth (valuation)?
Valuation information for Vaxess is not publicly available.
Can I buy Vaxess stock?
Vaxess shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vaxess's last funding round?
Vaxess's most recent funding round was Series C on March 27, 2026.
Who are the main investors in Vaxess?
Key investors in Vaxess include RA Capital Management, The Engine.
Will Vaxess IPO soon?
No public IPO plans have been announced for Vaxess.
How can I track Vaxess secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vaxess's secondary market activity and sign up for updates.